FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2898057859> ?p ?o ?g. }

• W2898057859 abstract "Gantenerumab, a fully human, anti-amyloid beta (Aβ) monoclonal antibody (mAb) that binds to and promotes removal of aggregated Aβ (plaques, fibrils, and oligomers), is under investigation as a disease-modifying treatment in early AD. Double-blind treatment with low-dose gantenerumab (105mg and 225mg) in the global, placebo-controlled SCarlet RoAD study (NCT01224106) was suspended for futility and the study converted to an open-label extension (OLE) to evaluate the safety, tolerability, and pharmacodynamics of gantenerumab gradually up-titrated to 1200 mg SC q4w. Initial OLE analyses confirmed that safety profile of gantenerumab remained unchanged with amyloid-related imaging abnormalities (ARIA) and injection-site reactions (ISR) as identified risks.1 Here we present data after up to 2 years' treatment with open-label gantenerumab. 154 study participants who did not have recurrent vasogenic edema (ARIA-E), >5 cerebral microhemorrhages/hemosiderosis (ARIA-H), or any condition potentially precluding safe participation, entered the OLE after a median of 78 weeks off-treatment. To reduce ARIA-E risk, gantenerumab doses were increased slowly using a 6- or 10-month titration scheme, based on apolipoprotein E4 genotype and last double-blind dose. Target dose and titration schemes were modelled based on all available data with mAb targeting aggregated amyloid, to achieve maximum amyloid reduction while maintaining safety and tolerability. Protocol measures included MRI monitoring and dosing algorithm. As of January 16, 2018, OLE duration ranged 12–101 weeks (median: 63.9 weeks). 103/154 patients received 1200mg gantenerumab for 1–81 weeks. ARIAs were detected in 47/133 patients with a post-baseline MRI; 38 patients had ARIA-E, 61% of whom had ARIA-H. ARIA-E incidence increased with dose (Table), with overall rate 28.6%. Most ARIAs (84%) were asymptomatic and non-serious. Incidence (79%) and severity of adverse events (including ISRs) remained comparable to SCarlet RoAD low-dose double-blind treatment. This updated Scarlet RoAD OLE safety analysis showed no new or unexpected findings with longer exposure to high-dose gantenerumab. ARIA-E rate increased with dose, but the titration appeared to reduce ARIA-E risk with overall incidence <30%. ARIAs appeared manageable with implemented protocol measures. These data support the use of titration to high-dose gantenerumab in the phase 3 GRADUATE program. 1. Andjelkovic, CTAD 2017 ." @default.
• W2898057859 created "2018-10-26" @default.
• W2898057859 creator A5002320307 @default.
• W2898057859 creator A5009189002 @default.
• W2898057859 creator A5018749214 @default.
• W2898057859 creator A5026149226 @default.
• W2898057859 creator A5037459780 @default.
• W2898057859 creator A5043928332 @default.
• W2898057859 creator A5050015669 @default.
• W2898057859 creator A5051452074 @default.
• W2898057859 creator A5068308578 @default.
• W2898057859 creator A5072019664 @default.
• W2898057859 creator A5083171778 @default.
• W2898057859 date "2018-07-01" @default.
• W2898057859 modified "2023-10-14" @default.
• W2898057859 title "O1‐09‐05: UPDATE ON THE SAFETY AND TOLERABILITY OF GANTENERUMAB IN THE ONGOING OPEN‐LABEL EXTENSION OF THE SCARLET ROAD STUDY IN PATIENTS WITH PRODROMAL ALZHEIMER'S DISEASE AFTER APPROXIMATELY 2 YEARS OF STUDY DURATION" @default.
• W2898057859 doi "https://doi.org/10.1016/j.jalz.2018.06.2382" @default.
• W2898057859 hasPublicationYear "2018" @default.
• W2898057859 type Work @default.
• W2898057859 sameAs 2898057859 @default.
• W2898057859 citedByCount "6" @default.
• W2898057859 countsByYear W28980578592019 @default.
• W2898057859 countsByYear W28980578592020 @default.
• W2898057859 countsByYear W28980578592022 @default.
• W2898057859 crossrefType "journal-article" @default.
• W2898057859 hasAuthorship W2898057859A5002320307 @default.
• W2898057859 hasAuthorship W2898057859A5009189002 @default.
• W2898057859 hasAuthorship W2898057859A5018749214 @default.
• W2898057859 hasAuthorship W2898057859A5026149226 @default.
• W2898057859 hasAuthorship W2898057859A5037459780 @default.
• W2898057859 hasAuthorship W2898057859A5043928332 @default.
• W2898057859 hasAuthorship W2898057859A5050015669 @default.
• W2898057859 hasAuthorship W2898057859A5051452074 @default.
• W2898057859 hasAuthorship W2898057859A5068308578 @default.
• W2898057859 hasAuthorship W2898057859A5072019664 @default.
• W2898057859 hasAuthorship W2898057859A5083171778 @default.
• W2898057859 hasConcept C111113717 @default.
• W2898057859 hasConcept C112705442 @default.
• W2898057859 hasConcept C126322002 @default.
• W2898057859 hasConcept C141071460 @default.
• W2898057859 hasConcept C197934379 @default.
• W2898057859 hasConcept C2777288759 @default.
• W2898057859 hasConcept C2778375690 @default.
• W2898057859 hasConcept C71924100 @default.
• W2898057859 hasConcept C98274493 @default.
• W2898057859 hasConceptScore W2898057859C111113717 @default.
• W2898057859 hasConceptScore W2898057859C112705442 @default.
• W2898057859 hasConceptScore W2898057859C126322002 @default.
• W2898057859 hasConceptScore W2898057859C141071460 @default.
• W2898057859 hasConceptScore W2898057859C197934379 @default.
• W2898057859 hasConceptScore W2898057859C2777288759 @default.
• W2898057859 hasConceptScore W2898057859C2778375690 @default.
• W2898057859 hasConceptScore W2898057859C71924100 @default.
• W2898057859 hasConceptScore W2898057859C98274493 @default.
• W2898057859 hasIssue "7S_Part_4" @default.
• W2898057859 hasLocation W28980578591 @default.
• W2898057859 hasOpenAccess W2898057859 @default.
• W2898057859 hasPrimaryLocation W28980578591 @default.
• W2898057859 hasRelatedWork W2021831895 @default.
• W2898057859 hasRelatedWork W2088986153 @default.
• W2898057859 hasRelatedWork W2103686849 @default.
• W2898057859 hasRelatedWork W2122556001 @default.
• W2898057859 hasRelatedWork W2146673033 @default.
• W2898057859 hasRelatedWork W2207503964 @default.
• W2898057859 hasRelatedWork W2319065640 @default.
• W2898057859 hasRelatedWork W3216317923 @default.
• W2898057859 hasRelatedWork W4319063555 @default.
• W2898057859 hasRelatedWork W4366989399 @default.
• W2898057859 hasVolume "14" @default.
• W2898057859 isParatext "false" @default.
• W2898057859 isRetracted "false" @default.
• W2898057859 magId "2898057859" @default.
• W2898057859 workType "article" @default.